Vedolizumab-associate diffuse interstitial lung disease in patients with ulcerative colitis: A case report

4Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.
Get full text

Abstract

BACKGROUND,Vedolizumab, a newer class of integrin antagonist biological agents, has been,applied to treat patients with moderate-to-severe Crohn’s disease (CD) and,ulcerative colitis (UC), especially for patients who are refractory to traditional,therapies and tumor necrosis factor antagonists. However, some rare but life-threatening adverse effects warrant pharmacovigilance. We describe the first fatal,case of vedolizumab-associated severe diffuse interstitial lung disease in China.,CASE SUMMARY,We present a case of new-onset diffuse parenchymal lung disease developing,under treatment with vedolizumab in a patient with UC. After two doses of,vedolizumab, he developed persistent fever and progressively worsening,dyspnea. Extensive workups, including bronchoalveolar lavage, transbronchial,lung biopsy and metagenomic next-generation sequencing, identified no,infectious causes, and other potential causes (such as tumors and cardiogenic,pulmonary edema) were also excluded. As a result, a diagnosis of vedolizumabrelated interstitial lung disease was established. Unfortunately, although corticost-eroids and empiric antibiotics were administered, the patient eventually died of,respiratory failure.,CONCLUSION,Vedolizumab-related interstitial lung disease in patients with UC is rare but,potentially lethal. Gastroenterologists and pulmonologists should be aware of,vedolizumab-related adverse drug reactions.

References Powered by Scopus

A method for estimating the probability of adverse drug reactions

9662Citations
N/AReaders
Get full text

Vedolizumab as induction and maintenance therapy for ulcerative colitis

2070Citations
N/AReaders
Get full text

Vedolizumab as induction and maintenance therapy for Crohn's disease

1771Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Forsythiae Fructuse extracts alleviates LPS-induced acute lung injury in mice by regulating PPAR-γ/RXR-α in lungs and colons

22Citations
N/AReaders
Get full text

Lung Involvement in Inflammatory Bowel Diseases: Shared Pathways and Unwanted Connections

12Citations
N/AReaders
Get full text

Advances and optimization strategies in bacteriophage therapy for treating inflammatory bowel disease

3Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Zhang, J., Liu, M. H., Gao, X., Dong, C., & Li, Y. X. (2022). Vedolizumab-associate diffuse interstitial lung disease in patients with ulcerative colitis: A case report. World Journal of Clinical Cases, 10(5), 1716–1722. https://doi.org/10.12998/wjcc.v10.i5.1716

Readers over time

‘22‘23‘24‘2501234

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

67%

Professor / Associate Prof. 1

17%

Researcher 1

17%

Readers' Discipline

Tooltip

Medicine and Dentistry 4

67%

Pharmacology, Toxicology and Pharmaceut... 2

33%

Save time finding and organizing research with Mendeley

Sign up for free
0